Scarlet Secures $50m Funding to Expand AI Medical Device Certification Platform
London-based medical technology company Scarlet has secured $50 million in a Series B funding round to scale its artificial intelligence-focused software certification platform across the United States and Asia-Pacific markets. The investment was led by Headline, with additional contributions from Notion Capital, Atomico, and Creandum. The company plans to use the capital to recruit additional AI reviewers and engineers to handle technical documentation uploads and regulatory assessments.
Expanding Regulatory Review and Market Reach
Scarlet designed its platform to specialize in the review and certification of software-based medical devices and artificial intelligence applications. According to the company, the platform allows users to upload technical documentation in various formats for evaluation by qualified personnel to determine compliance with relevant regulations. The organization has previously secured designations as a Third-Party Review Organization from European, British, and United States regulators.
- Funding round total: $50 million in Series B capital
- Lead investor: Headline
- Target expansion regions: United States and Asia-Pacific markets
Continuous Monitoring and Governance in Healthcare AI
As the adoption of artificial intelligence grows within the life sciences sector, regulatory bodies and developers emphasize the importance of robust governance frameworks. Scarlet operates a subscription-based model that provides ongoing surveillance, annual audits, and product change reviews to help ensure that certified devices maintain compliance as software upgrades occur. Current customers utilizing AI-driven tools include period tracking application creator Flo Health and radiology specialist DeepHealth.
Market analysts note that the broader artificial intelligence sector across healthcare, pharmaceuticals, and medical devices continues to experience substantial financial growth, driven by increasing integration into clinical and administrative workflows. Industry experts emphasize that continuous compliance monitoring, strict data access restrictions, and human oversight remain essential components for safely deploying software medical devices in clinical environments.
